AUTL

AUTL

USD

Autolus Therapeutics plc American Depositary Share

$2.240-0.130 (-5.485%)

リアルタイム価格

Healthcare
バイオテクノロジー
英国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$2.370

高値

$2.370

安値

$2.210

出来高

0.19M

企業ファンダメンタルズ

時価総額

596.1M

業種

バイオテクノロジー

United Kingdom

取引統計

平均出来高

2.19M

取引所

NMS

通貨

USD

52週レンジ

安値 $1.105現在値 $2.240高値 $5

関連ニュース

Analyst Upgrades

Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics with a Buy and maintains $10 price target.

もっと見る
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
GlobeNewswire

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients still in remission at 24 months38% of ongoing responders did not receive any subsequent

もっと見る
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityOpinion follows FDA approval and

もっと見る
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)